Since GSK-3 inhibition efficiently suppresses NF-κB in pancreatic cancer cells, and downregulates NF-κB targets associated with chemotherapy resistance such as XIAP and Bcl-XL, it seemed reasonable to predict that this would also sensitize these cells to gemcitabine. The gene discussed is XIAP; the disease is pancreatic neoplasm.